Share Name Share Symbol Market Type Share ISIN Share Description
Hvivo Plc LSE:HVO London Ordinary Share GB00B6ZM0X53 ORD 5P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 14.75 14.50 15.00 14.75 14.75 14.75 0.00 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 11.0 -18.9 -21.3 - 12

hVIVO plc Notice of Interim Results

23/08/2019 7:00am

UK Regulatory (RNS & others)

Hvivo (LSE:HVO)
Historical Stock Chart

3 Months : From Aug 2019 to Nov 2019

Click Here for more Hvivo Charts.


RNS Number : 9346J

hVIVO plc

23 August 2019

hVIVO plc

("hVIVO" or the "Company")

Notice of Interim Results

London, UK 23 August 2019: hVIVO plc (AIM: HVO), an industry leading clinical development services business pioneering human disease models based upon viral challenge, will announce its interim financial results for the six months ended 30 June 2019 on Thursday 19 September 2019.

A presentation and webcast for analysts will be held at 11.00am BST at the offices of FTI Consulting, 200 Aldersgate, Aldersgate Street, London, EC1A 4HD, with registration and coffee from 10.45am. A webcast recording of the event will be available on the Company's website.

For further information please contact:

 hVIVO plc 
 Trevor Phillips (Executive Chairman)                     +44 207 756 1300 
 Fleur Wood (EVP, Investor Relations & Communications) 
 Numis Securities Limited                                  +44 207 260 1000 
 Freddie Barnfield / Huw Jeremy (Nominated Adviser) 
 James Black (Corporate Broking) 
 FTI Consulting 
 Simon Conway / Victoria Foster Mitchell                  +44 203 727 1000 

Notes to Editors:

hVIVO plc ("hVIVO") is pioneering a human-based clinical trial platform to accelerate drug and vaccine development in respiratory and infectious diseases. Leveraging human disease models in flu, RSV, HRV and respiratory indications, the hVIVO platform captures disease in motion, illuminating the entire disease life cycle from healthy to sick and back to health. Based in the UK, market leader hVIVO has conducted more than 50 clinical studies and inoculated over 2500 volunteers.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit



(END) Dow Jones Newswires

August 23, 2019 02:00 ET (06:00 GMT)

1 Year Hvivo Chart

1 Year Hvivo Chart

1 Month Hvivo Chart

1 Month Hvivo Chart
Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191117 00:51:08